No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GKOS240621C100000
- 14.50
- +6.80+88.31%
15min DelayClose May 31 16:00 ET
14.50High14.50Low
14.50Open7.70Pre Close1 Volume10 Open Interest100.00Strike Price1.45KTurnover57.31%IV1.40%PremiumJun 21, 2024Expiry Date12.72Intrinsic Value100Multiplier19DDays to Expiry1.78Time Value100Contract SizeAmericanOptions Type0.8415Delta0.0164Gamma7.88Leverage Ratio-0.1055Theta0.0421Rho6.63Eff Leverage0.0623Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)
Form 144 | Glaukos(GKOS.US) Director Proposes to Sell 560K in Common Stocks
SEC FILLINGS DISCLOSED/ May 30, $Glaukos(GKOS.US)$ Director Kliman Gilbert H intends to sell 5,000 shares of its common stock on May 30, with a total market value of approximately $560K. Kliman Gilb
Is Glaukos (NYSE:GKOS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $130
Citi analyst Joanne Wuensch maintains $Glaukos(GKOS.US)$ with a buy rating, and adjusts the target price from $120 to $130.According to TipRanks data, the analyst has a success rate of 62.2% and a tot
Comments
Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.
Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%
Last week’s PDUFAs:
$Arcutis Biotherapeutics(ARQT.US$ :![]()
Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15![]()
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14![]()
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
$Arcutis Biotherapeutics(ARQT.US$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US$ : Approved ...
7
1
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US$ $Vertex Pharmaceuticals(VRTX.US$ $OptiNose(OPTN.US$ $Arcutis Biotherapeutics(ARQT.US$ $Calliditas Therapeutics(CALT.US$ $bluebird bio(BLUE.US$ $Glaukos(GKOS.US$ $Ionis Pharmaceuticals(IONS.US$ $Amgen(AMGN.US$ $Merck & Co(MRK.US$
7
2
Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.
Read more